NanoFlu/NVX CoV 2373/RSV - Novavax
Alternative Names: NanoFlu/NVX-CoV2373/RSV; NanoFlu/NVX-CoV2373/RSV combination vaccine - NovavaxLatest Information Update: 19 May 2021
Price :
$50 *
At a glance
- Originator Novavax
- Class COVID-19 vaccines; Influenza virus vaccines; Protein vaccines; Proteins; Respiratory syncytial virus vaccines; Synthetic vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical COVID 2019 infections; Influenza virus infections; Respiratory syncytial virus infections
Most Recent Events
- 01 Mar 2021 Preclinical trials in COVID-2019 infections (Prevention) in USA (Parenteral) before March 2021 (Novavax FORM 10-K, March 2021)
- 01 Mar 2021 Preclinical trials in Influenza virus infections (Prevention) in USA (Parenteral) before March 2021 (Novavax FORM 10-K, March 2021)
- 01 Mar 2021 Preclinical trials in Respiratory syncytial virus infections (Prevention) in USA (Parenteral) before March 2021 (Novavax FORM 10-K, March 2021)